Latest Content

Trodelvy plus Keytruda extended benefit beyond progression in PD-L1-positive metastatic triple-negative breast cancer.

A survivor reflects on scanxiety, changing follow-up schedules and adapting when a cancer scare disrupted the routine that had brought reassurance.

Dr. John Marshall answers common questions about colorectal cancer, including biomarker testing, treatment options, second opinions and more.

A uterine cancer survivor shares her journey through severe bleeding, emergency surgery, daily radiation treatments, and managing post-chemo GI issues.

A survivor shares her personal journey with stage 2A breast cancer, from choosing a bilateral mastectomy to navigating chemotherapy and hair loss.

A 26-year story of survival: Overcoming myelofibrosis, finding a match for a bone marrow transplant, and enduring severe GVHD to help others.

Learn the answers to common questions about bladder cancer, including symptoms, risk factors, stages, BCG therapy, side effects and treatment options.

MosunPola improved progression-free survival and response rates over R-GemOx in transplant-ineligible relapsed large B-cell lymphoma.

Appeals, peer-to-peer reviews and external reviews often overturn insurance denials, helping patients access recommended cancer care.

A breast cancer survivor honors her brother’s legacy 50 years after his death by updating her donor registry status to support vital cancer research.

Nurse-led ONS study identifies strategies to reduce CLABSI risk in hematologic cancer care through standardized workflows and documentation.

Investigational bispecific antibody pumitamig achieved a 70% response rate and disease control in all evaluable patients with advanced NSCLC.

ASCO 2026 highlighted advances in pancreatic, breast, sarcoma, lung and prostate cancers that may reshape treatment.